CNS and oncology appear prime targets for Proteus and Otsuka's 'digital medicines'
This article was originally published in Scrip
In another sign of the blurring boundaries between therapeutics and medical technology, Otsuka Pharmaceutical has put down its marker in the area of drug compliance management, linking up with Proteus Digital Health for the joint development and commercialisation of "digital medicines".
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.